News Image

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

Provided By GlobeNewswire

Last update: Jul 25, 2024

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-022/KN-D38 study will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024.

Read more at globenewswire.com

IO BIOTECH INC

NASDAQ:IOBT (6/13/2025, 8:11:12 PM)

After market: 1.35 0 (0%)

1.35

-0.15 (-10%)



Find more stocks in the Stock Screener

Follow ChartMill for more